Pulmonary Hypertension News – Pulmonary Hypertension News
WEBSep 18, 2024 · Riociguat found safe, effective for PAH with coexisting conditions. Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials.
Different Uptravi maintenance doses led to similar outcomes: Study
WEB5 hours ago · Investigating patient outcomes with varying Uptravi maintenance doses. Uptravi is approved for adults with PAH, a condition marked by high blood pressure caused by the narrowing of blood vessels that transport blood through the lungs.
Riociguat found safe, effective for PAH with coexisting conditions
WEB5 days ago · In the study, an international team of researchers assessed the effect of Adempas on PAH patients with coexisting cardiometabolic diseases, namely obesity, hypertension, diabetes mellitus, and coronary artery disease, which is when the blood supply to the heart is reduced or interrupted. They analyzed pooled data from several clinical trials, including the Phase 3 PATENT-1 study (NCT00810693 ...
Approval of new treatments for pulmonary hypertension prompts...
WEBApr 3, 2024 · The pulmonary hypertension (PH) community is buzzing with excitement! It’s not every week that the U.S. Food and Drug Administration (FDA) approves two new treatments for a rare disease like PH. This monumental achievement is a testament to the dedication and passion of researchers, scientists, and the rest of the medical community.
Winrevair, PAH treatment for adults, likely available soon in US
WEBWinrevair, an injection PAH treatment, may be given at home with training. In STELLAR (NCT04576988), the Phase 3 clinical trial that supported Winrevair’s approval, the …
Mosliciguat’s early efficacy results support launch of Phase 2 study
WEBSep 13, 2024 · The proof-of-concept Phase 1b clinical trial ATMOS (NCT03754660) assessed mosliciguat’s safety, tolerability, and efficacy in people with pulmonary artery hypertension or chronic thromboembolic pulmonary hypertension, a rare form of PH associated with blood clot formation. A total of 38 participants, ages 18 to 80, received a daily dose of mosliciguat using a dry powder inhaler (DPI).
Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBJul 8, 2019 · A study found that an estimated right ventricular systolic pressure (eRVSP) of 30 mmHg or higher is linked to increased mortality in patients with pulmonary hypertension (PH). The study used echocardiography to measure eRVSP levels and adjusted for age, sex, and left heart disease.
Top 10 Pulmonary Hypertension Stories of 2022 | Key Topics:...
WEBDec 29, 2022 · Opsumit (macitentan) is a daily oral therapy that’s approved to treat pulmonary arterial hypertension (PAH). In this study, researchers analyzed data from the Phase 3 clinical trial SERAPHIN (NCT00660179) and its open-label extension (NCT00667823) to evaluate the therapy’s long-term effect on survival.Nearly three-quarters (73.3%) of patients were alive at five years, and more than half ...
Top 10 Pulmonary Hypertension Stories of 2021 – Pulmonary...
WEBJan 3, 2022 · A recap of the most-read news articles about PH research, treatment, and clinical trials in 2021. Learn about the latest advances in endothelial cells, oral medications, nitric oxide, and more.
Pulmonary Hypertension Death Rate in US Increased for 20 Years
WEBOct 17, 2022 · While all types of pulmonary hypertension are associated with increased mortality, some reports suggest higher death rates for those caused by left-heart disease, and common lung conditions.. Previous studies had shown that the age-adjusted PH-related mortality rate in the U.S. remained stable from 1980 to 2001, but then gradually increased until 2010 — from 5.2 to 6.5 deaths per 100,000 ...
Skip to content